Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UC-MSC for Left Ventricular Dysfunction After Acute Myocardial Infarction
NCT03902067Phase 1Withdrawn
- Sponsor
- Shanghai Life Science Technology
- Start
- Dec 2024
- Primary completion
- Dec 2025
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of human umbilical cord mesenchymal stem cells in left ventricular dysfunction and acute myocardial infarction (AMI) (2 arms), sponsored by Shanghai Life Science Technology. Primary endpoint: Major Adverse Cardiac Events at 12 months. Planned start Dec 2024; status: withdrawn.
02
Drugs
human umbilical cord mesenchymal stem cells
03
Conditions
left ventricular dysfunctionacute myocardial infarction (AMI)
Beyond the preview
Go deeper on NCT03902067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03902067.